Division of Teva Pharmaceutical Industries Ltd.
Latest From Galena SP
RXi thought it had solved the RNAi delivery issue but was focused on dermatology and ophthalmology. New CEO Dispersyn thought the platform offered more lucrative promise as a way of optimizing IO therapy.
Preparing to meet with FDA in December to plan next steps for NeuVax in triple-negative breast cancer, Sellas reveals 26-month data that show further clinical benefit compared with a 19-month interim look. Firm still hopes to out-license the vaccine candidate.
- Therapeutic Areas
- Czech Republic
- Eastern Europe
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
- Milan Novotny, Director
- Contact Info
Phone: 420 553 64 11 11
Opava-Komarov, 747 70
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.